Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691389 | 0.93 | PTK2 (0.64) | PTK2MAPK1MAPK3CLCN2KCNJ6 | |
| SCHEMBL1292984 | 0.91 | PTK2 (0.65) | PTK2MAPK1MAPK3KCNJ6KCNJ5 | |
| SCHEMBL689984 | 0.91 | PTK2 (0.64) | PTK2MAPK1MAPK3KCNJ6KCNJ5 | |
| SCHEMBL690574 | 0.89 | PTK2 (0.80) | PTK2MAPK1MAPK3KCNJ6KCNJ5 | |
| SCHEMBL691295 | 0.88 | PTK2 (0.78) | PTK2MAPK1MAPK3KCNJ6KCNJ5 | |
| SCHEMBL1292954 | 0.85 | PTK2 (0.65) | PTK2MAPK1MAPK3KCNJ6KCNJ5 | |
| SCHEMBL691083 | 0.85 | PTK2 (0.66) | PTK2KCNJ6KCNJ5KCNJ3NTRK1 | |
| SCHEMBL691210 | 0.84 | PTK2 (0.62) | PTK2MAPK1MAPK3KCNJ6KCNJ5 | |
| SCHEMBL691573 | 0.84 | MAPK1 (0.50) | PTK2MAPK1MAPK3CLCN2KDM4C | |
| SCHEMBL692011 | 0.83 | PTK2 (0.80) | PTK2MAPK1MAPK3KCNJ6KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| US-9012479-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.